[2-Sulfo-9-fluorenylmethoxycarbonyl]3–exendin-4—a long-acting glucose-lowering prodrug
- 2 May 2003
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 305 (2), 386-391
- https://doi.org/10.1016/s0006-291x(03)00715-0
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.Proceedings of the National Academy of Sciences, 1992
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992
- Glucagon-like peptide-1(7–37)/(7–36)amide is a new incretinMolecular and Cellular Endocrinology, 1992
- Solubilization of active GLP-1 (7-36)amide receptors from RINm5F plasma membranesFEBS Letters, 1992
- Glucagon‐like peptide‐1(7–36) amide is a new incretin/enterogastrone candidateEuropean Journal of Clinical Investigation, 1991
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.JCI Insight, 1987
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- The incretin concept todayDiabetologia, 1979
- STUDIES ON THE PHYSIOLOGY OF SECRETINAmerican Journal of Physiology-Legacy Content, 1930